Downloads: 0 | Views: 15
Analysis Study Research Paper | Obstetrics and Gynecology | India | Volume 11 Issue 11, November 2022
Mifepristone and Misoprostol Compared with Misoprostol alone for Delivery after Fetal Death between 14 and 28 Weeks of Gestation
Dr. J. Rishitha Priyanka  | Dr. Kalpana 
Abstract: Objective: To assess the efficacy of pretreatment with mifepristone before misoprostol, compared with misoprostol alone, for termination of pregnancy after a fetal death in the second trimester. Methods: This prospective, double blind, placebo-controlled trial randomized women requiring a termination of pregnancy after fetal death between 14 and 28 weeks of gestation to placebo or 200 mg mifepristone orally 24-48 hours before the termination of pregnancy with misoprostol (400 micrograms every 6 hours vaginally for women at 24 weeks of gestation or less, and 200 micrograms every 4 hours vaginally for women at 24 weeks of gestation or more). Based on a median labor with misoprostol alone in the second trimester of 13 hours, a sample size of 66 women per group was planned to compare the primary outcome of time from administration of misoprostol to delivery. Results: From April 2021 to October 2022, 66 women were randomized (34 to placebo and 32 to mifepristone). There were no differences in the characteristics between the two groups. The median time for the primary outcome of administration of misoprostol to delivery in the placebo group was 10.5 hours, compared with 6.8 hours in the treatment group (hazard ratio 2.41 95% CI 1.39-4.17, P5.002). Women in the placebo group required more doses of misoprostol (3.4 vs 2.1, P5.002) and more misoprostol overall (1,181.8 micrograms, vs 767.7 micrograms, P5.003). There was no difference in maternal complications between the two groups. Women in the mifepristone group reported improved perception of the procedure. Conclusion: The sequential use of mifepristone and misoprostol for the termination of pregnancy after fetal deaths between 14 and 28 weeks of gestation reduces the time to delivery, compared with the use of misoprostol alone, with no worsening of maternal complications.
Keywords: Mifepristone, Misoprostol, Termination of Pregnancy
Edition: Volume 11 Issue 11, November 2022,
Pages: 704 - 710
Similar Articles with Keyword 'Mifepristone'
Comparative Studies, Obstetrics and Gynecology, India, Volume 10 Issue 6, June 2021Pages: 1537 - 1541
Comparative Study of Efficacy and Safety of Mifepristone and Foley's Catheter in Induction of Labour
Amrutha .A .V | Shaila C | Ravi Karad 
Research Paper, Obstetrics and Gynecology, India, Volume 9 Issue 11, November 2020Pages: 1063 - 1065
Safety of Medical Methods in Second Trimester Abortion at a District Hospital in Tamilnadu
Dr. Uma Maheswari